-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
WCLC News
-
IASLC Award Recognizes Importance of Cancer Care Teamwork
The IASLC awarded four cancer care teams from around the globe with one of the association’s most prestigious award—the IASLC Cancer Care Team Award (CCTA). The winning teams were announced during the IASLC 2020 World Conference on Lung Cancer Singapore. The CCTA recognizes a single institution in North America, Europe, Latin America, and Asia/Rest of…
-
More Options Needed After First-Line Chemoimmunotherapy in Lung Cancer
As an increasing number of immunotherapy treatments find their way into the front-line treatment of solid tumors, including lung cancer, clinicians are often faced with a lack of options when choosing systemic therapies after chemoimmunotherapy. During the Education Session, “Choosing Systemic Therapies After Chemoimmunotherapy in NSCLC” three speakers provided updates on the current second-line options…
-
Immunohistochemistry’s Important Role in Diagnosis of Thoracic Cancers Explained in a New Atlas
The latest in the series of diagnostic Atlases has been published by the IASLC and its Pathology Committee. Following the highly successful editions on ALK, EGFR, ROS1 and PD-L1, this latest Atlas takes a comprehensive look at diagnostic immunohistochemistry (IHC) and its role in thoracic pathology. The editorial team of Drs. Yasushi Yatabe, Alain Borczuk,…
-
Program Trains Patient Research Advocates to be STARS
What does it take to become a star in any setting? Passion, knowledge, and drive. When it comes to understanding the science of lung cancer, sometimes the experts are the patients themselves. The IASLC is looking for patients and caregivers who want to learn about lung cancer science and research, as well as develop their…
-
Enhancing Your WCLC Experience with Twitter
Even those who are unfamiliar with social media platforms can find Twitter to be an easy way to discuss research and collaborate with colleagues. If you do not already have a Twitter account, you should consider setting one up now! During a virtual conference, Twitter is the best possible replacement for the hallway conversations that…
-
IASLC President Discusses Accomplishments, Adjustments, and The Year Ahead
Dr. Tetsuya Mitsudomi joined the Board of Directors of IASLC in 2011 and has served as its board president since 2019. IASLC awarded Dr. Mitsudomi its Mary J. Matthews Pathology/Translational Research Award in 2013 for a lifetime achievement in pathology and translational research of thoracic malignancies. Dr. Mitsudomi, professor in the Division of Thoracic Surgery…
-
Finding the Benefits of the Virtual World: A Conversation with Dr. Heather Wakelee
Heather Wakelee, MD, is the President-Elect of the IASLC and will assume presidential responsibilities at the 2021 WCLC in September. She is the Chief of the Division of Oncology at Stanford University and Deputy Director of the Stanford Cancer Institute. She is also the principal investigator of numerous clinical trials and lead investigator for the…
-
Interim Chief Scientific Officer Dr. Giorgio Scagliotti Brings Vast IASLC Knowledge to Role
With a long history in leadership positions at the IASLC, Dr. Scagliotti is fully prepared to help guide the society’s scientific projects through a transition period. Dr. Scagliotti, is professor of medical oncology at the University of Turin School of Medicine, Italy, where he is also a member of the administrative board. He is also…
-
Prof. Caroline Dive Honored with Mary J. Matthews Pathology/Translational Research Award for Work with CTCs
Caroline Dive, CBE, PhD, FBPhS, FMedSci, Director of the CRUK Manchester Institute Cancer Biomarker Centre, University of Manchester, has been recognized by the IASLC with the Mary J. Matthews Pathology/Translational Research Award. The award recognizes an IASLC scientist for a lifetime achievement in pathology and translational research of thoracic malignancies. “I am utterly delighted and…
-
Dr. Pan-Chyr Yang Honored by IASLC for Contributions to Lung Cancer Prevention
Pan-Chyr Yang, MD, PhD, Chair Professor at the National Taiwan University Hospital and Academician of Academia Sinica, Taiwan, will be recognized by the International Association for the Study of Lung Cancer (IASLC) with the Joseph W. Cullen Prevention/Early Detection Award at the fully virtual IASLC 2020 World Conference on Lung Cancer (WCLC). This award recognizes…
View ILCN Archives
Provider Resources
Popular Articles